Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05215548 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment reopened Eligibility criteria expanded, about 15 words · Secondary endpoints: details revised at 3 of 5 entries · Site details revised at 2 of 2 sites Show 3 more changesShow less
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 3 of 5 entries
    • Site details revised at 2 of 2 sites
  2. Primary completion date: Jul 2024 to Oct 2026 Trial status: Recruiting to Active, Not Recruiting · Completion date: Jul 2026 to Oct 2027 · Site details revised at 2 of 2 sitesv4 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Jul 2026 to Oct 2027
    • Site details revised at 2 of 2 sites
  3. Eligibility criteria expanded, about 13 wordsv3 See this version in full on ClinicalTrials.gov ↗
  4. Trial status: Active, Not Recruiting to Recruiting Site details revised at 2 of 2 sites · Study title shortened, about 14 wordsv2 Show 2 more changesShow less
    • Site details revised at 2 of 2 sites
    • Study title shortened, about 14 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Our project is going to enroll patients with stage IV NSCLC with EGFR mutation and evaluate whether primary tumor resection after receiving the afatinib can prolong survival. This project is supposed to establish a new treatment protocol for stage IV NSCLC with EGFR mutation.
Trial Details
NCT Number NCT05215548
Lead Sponsor National Taiwan University Hospital
Conditions NSCLC Stage IV
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov